How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression? A VAST-D...

Area of Science:

• Psychiatry
• Clinical Psychology
• Mental Health Research

Background:

• Positive mental health (PMH) is a primary patient-reported goal in major depressive disorder (MDD) treatment.
• Limited research exists on systematically measuring PMH and its predictive value for treatment outcomes.
• This study investigates factors associated with PMH and its impact on outcomes in treatment-resistant depression.

Purpose of the Study:

• To identify features associated with positive mental health (PMH) in major depressive disorder (MDD) patients.
• To examine the predictive value of PMH for treatment outcomes in major depressive disorder (MDD).
• To explore the role of PMH in treatment-resistant depression.

Main Methods:

• Utilized data from the VA Augmentation and Switching Treatments for Depression trial (NCT01421342), involving 1522 participants.
• Assessed PMH using a novel 7-item self-rated questionnaire at baseline and during 12 weeks of treatment.
• Compared outcomes across three next-step treatments: switching to bupropion (S-BUP), combining with bupropion (C-BUP), or augmenting with aripiprazole (A-ARI).

Main Results:

• Low baseline PMH scores correlated with increased depression severity, chronicity, suicidal ideation, anxiety, PTSD, grief, and lower quality of life.
• High baseline PMH scores predicted a greater likelihood of remission.
• PMH scores improved with treatment, particularly with aripiprazole augmentation (A-ARI) compared to switching to bupropion (S-BUP), and improved PMH was linked to higher remission and response rates.

Conclusions:

• Positive mental health (PMH) is a significant indicator of treatment success in major depressive disorder (MDD).
• Addressing deficiencies in PMH may enhance treatment optimization and patient outcomes.
• PMH measurement and targeted interventions represent a valuable approach in managing MDD.